Research programme : cancer metabolism therapeutics - Lead Discovery Center/SOTIO
Alternative Names: SO L103Latest Information Update: 28 Jun 2022
At a glance
- Originator Max Planck Institute for Biology of Ageing
- Developer SOTIO; The Lead Discovery Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in Czech Republic
- 28 May 2021 No recent reports of development identified for research development in Cancer in Germany
- 29 May 2018 Preclinical trials in Cancer in Czech Republic (unspecified route) prior to May 2018 (SOTIO pipeline, May 2018)